Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, recently completed an animal study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics. “Results from the small animal study produced positive endpoint results, demonstrating that Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre- and post-dosing time points. Mechanical hyperalgesia was additionally reduced on day seven at the pre-dose time point. ‘These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction,’ said Eric Weisblum, CEO of Silo Pharma. ‘This data is extremely promising for patients suffering from fibromyalgia and rheumatoid arthritis…,’” a recent article reads. “Silo Pharma aims to leverage the effects of ketamine via a patented administration method developed in partnership with Zylo Therapeutics Inc. called ‘Z-pod.’ The company’s ketamine study aimed to demonstrate that Z-pod can hold and distribute ketamine and time-release the drug while diminishing potential hallucinogenic side effects.”
To view the full article, visit https://ibn.fm/PzXNk
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.